97 related articles for article (PubMed ID: 7687513)
1. Substance P-like immunoreactivity and analgesic effects of vibratory stimulation on patients suffering from chronic pain.
Guieu R; Tardy-Gervet MF; Giraud P
Can J Neurol Sci; 1993 May; 20(2):138-41. PubMed ID: 7687513
[TBL] [Abstract][Full Text] [Related]
2. Met-enkephalin and beta-endorphin are not involved in the analgesic action of transcutaneous vibratory stimulation.
Guieu R; Tardy-Gervet MF; Giraud P
Pain; 1992 Jan; 48(1):83-88. PubMed ID: 1738578
[TBL] [Abstract][Full Text] [Related]
3. Long-term high frequency transcutaneous electrical nerve stimulation (hi-TNS) in chronic pain. Clinical response and effects on CSF-endorphins, monoamine metabolites, substance P-like immunoreactivity (SPLI) and pain measures.
Almay BG; Johansson F; von Knorring L; Sakurada T; Terenius L
J Psychosom Res; 1985; 29(3):247-57. PubMed ID: 2411923
[TBL] [Abstract][Full Text] [Related]
4. Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc.
Lindh C; Liu Z; Lyrenäs S; Ordeberg G; Nyberg F
Scand J Rheumatol; 1997; 26(6):468-72. PubMed ID: 9433409
[TBL] [Abstract][Full Text] [Related]
5. Objective evaluation of pain in various spinal diseases: neuropeptide immunoreactivity in the cerebrospinal fluid.
Imasato H; Nagata K; Hashimoto S; Komori H; Inoue A
Spinal Cord; 1997 Nov; 35(11):757-62. PubMed ID: 9392047
[TBL] [Abstract][Full Text] [Related]
6. [Met-enkephalin and substance P. Comparison of CSF levels in patients with chronic pain based on a sampling procedure].
Guieu R; Tardy-Gervet MF; Giraud P; Boudouresque F
Rev Neurol (Paris); 1993; 149(6-7):398-401. PubMed ID: 7508141
[TBL] [Abstract][Full Text] [Related]
7. Analgesic effects of vibration and transcutaneous electrical nerve stimulation applied separately and simultaneously to patients with chronic pain.
Guieu R; Tardy-Gervet MF; Roll JP
Can J Neurol Sci; 1991 May; 18(2):113-9. PubMed ID: 1712660
[TBL] [Abstract][Full Text] [Related]
8. Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromes.
Jost S; Reuner C; Geiger J; Mohadjer M; Milios E; Cramer H
Eur Arch Psychiatry Clin Neurosci; 1991; 241(2):109-12. PubMed ID: 1834180
[TBL] [Abstract][Full Text] [Related]
9. Naloxone does not reverse the pain-reducing effect of vibratory stimulation.
Lundeberg T
Acta Anaesthesiol Scand; 1985 Feb; 29(2):212-6. PubMed ID: 3976336
[TBL] [Abstract][Full Text] [Related]
10. Vibratory stimulation for the alleviation of chronic pain.
Lundeberg TC
Acta Physiol Scand Suppl; 1983; 523():1-51. PubMed ID: 6609524
[TBL] [Abstract][Full Text] [Related]
11. Prevaccination with diluted Freund adjuvant prevents the development of chronic pain and transient release of cerebrospinal fluid substance P in adjuvant-induced arthritis in rats.
Calvino B; Couraud JY; Besson JM
Pain; 1994 Aug; 58(2):211-217. PubMed ID: 7529393
[TBL] [Abstract][Full Text] [Related]
12. Tissue concentration and release of substance P-like immunoreactivity in the dental pulp.
Brodin E; Gazelius B; Olgart L; Nilsson G
Acta Physiol Scand; 1981 Feb; 111(2):141-9. PubMed ID: 6169251
[TBL] [Abstract][Full Text] [Related]
13. Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.
Nutt JG; Mrox EA; Leeman SE; Williams AC; Engel WK; Chase TN
Neurology; 1980 Dec; 30(12):1280-5. PubMed ID: 6161319
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.
Cramer H; Schaudt D; Rissler K; Strubel D; Warter JM; Kuntzmann F
J Neurol; 1985; 232(6):346-51. PubMed ID: 2416886
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid neurotransmitter changes during the perioperative period in patients undergoing total knee replacement: a randomized trial.
Buvanendran A; Kroin JS; Della Valle CJ; Moric M; Tuman KJ
Anesth Analg; 2012 Feb; 114(2):434-41. PubMed ID: 22156332
[TBL] [Abstract][Full Text] [Related]
16. Effect of vibratory stimulation on experimental and clinical pain.
Lundeberg T; Abrahamsson P; Bondesson L; Haker E
Scand J Rehabil Med; 1988; 20(4):149-59. PubMed ID: 3266033
[TBL] [Abstract][Full Text] [Related]
17. Pain alleviation by vibratory stimulation.
Lundeberg T; Nordemar R; Ottoson D
Pain; 1984 Sep; 20(1):25-44. PubMed ID: 6333660
[TBL] [Abstract][Full Text] [Related]
18. Substance P mechanism in cluster headache: evaluation in plasma and cerebrospinal fluid.
Sicuteri F; Fanciullacci M; Geppetti P; Renzi D; Caleri D; Spillantini MG
Cephalalgia; 1985 Sep; 5(3):143-9. PubMed ID: 2412704
[TBL] [Abstract][Full Text] [Related]
19. Delta-Opioid receptor modulation of the release of substance P-like immunoreactivity in the dorsal horn of the rat following mechanical or thermal noxious stimulation.
Zachariou V; Goldstein BD
Brain Res; 1996 Oct; 736(1-2):305-14. PubMed ID: 8930337
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease.
Rösler N; Reuner C; Geiger J; Rissler K; Cramer H
Peptides; 1990; 11(1):181-3. PubMed ID: 1692993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
